Written by: Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates
Download Here

For patients with Non‐Small Cell Lung Cancer (NSCLC) that have a del 19 EGFR mutation appropriate for first‐line treatment with an epidermal growth factor receptor (EGFR) Inhibitor, Afatinib (Gilotrif) has a clear overall survival (OS) benefit compared to chemotherapy. If another EGFR inhibitor is being prescribed for a patient with a del 19 EGFR mutation, the pharmacist will contact the Physician to determine why the current therapy was chosen.

Continue reading EGFR Inhibitors

Read More

Written By: Chris Sellers, RPh Area Manager, Texas Oncology
Download Here

The purpose is to provide management of common adverse events, follow-up with patients and dose modifications. Dose adjustments are common and greatly reduced frequency and severity of adverse reactions.  Continue reading NSCLC Afatinib Management

Read More